Rigel Pharmaceuticals announced that final Phase 3 trial data for GAVRETO (pralsetinib) as a first-line treatment for RET fusion-positive non-small cell lung cancer (NSCLC) will be presented at ASCO 2026, showing improved progression-free survival and response rates over standard care. Additionally, data from Phase 1/2 trials of pralsetinib in RET-altered thyroid cancer and real-world evidence supporting REZLIDHIA (olutasidenib) for relapsed/refractory IDH1-mutated acute myeloid leukemia (AML) were presented. These findings highlight the clinical relevance of Rigel's oncology portfolio and suggest olutasidenib may be an effective post-venetoclax therapy for AML patients. The presentations at ASCO and EHA 2026 will further inform treatment strategies for these difficult-to-treat cancers.
On November 12, 2026, Nokia executive Pallavi Mahajan acquired 89 shares of Nokia Corporation at a price of €7.63 per share. This insider purchase is officially reported under EU Market Abuse Regulation Article 19. Such transactions by company execut...
David Heard, a senior manager at Nokia Corporation, purchased 1,139 shares of the company on November 12, 2026, at a price of €7.63 per share. This transaction was reported under EU Market Abuse Regulation, signaling insider confidence or strategic i...
Victoria Hanrahan, a senior executive at Nokia Corporation, purchased 6 shares of Nokia stock at a price of €7.63 per share on November 12, 2026. This transaction was reported under EU Market Abuse Regulation Article 19, indicating transparency in in...
Louise A. Fisk, a senior executive at Nokia Corporation, acquired 235 shares of Nokia stock at a price of €7.63 per share on November 12, 2026. This transaction was reported under the EU Market Abuse Regulation, signaling insider activity. Such purch...
Nokia executive David A. Heard purchased 1,139 shares of Nokia stock at a price of €7.63 per share on November 12, 2026. This transaction was reported under EU Market Abuse Regulation Article 19, indicating compliance with market transparency rules. ...
